RET, ret proto-oncogene, 5979

N. diseases: 607; N. variants: 162
Disease: Solid Neoplasm ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.050 Biomarker phenotype BEFREE RET fusions in solid tumors. 31715421 2019
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.050 Biomarker phenotype BEFREE The RET fusion is considered as the potential novel target in solid tumors. 30210625 2018
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.050 Biomarker phenotype BEFREE AE = adverse event CI = confidence interval C<sub>ss,max</sub> = maximum steady-state plasma concentration DCR = disease control rate EGFR = epidermal growth factor receptor ILD = interstitial lung disease MTC = medullary thyroid cancer ORR = objective response rate PFS = progression-free survival PK = pharmacokinetics RECIST = Response Evaluation Criteria in Solid Tumors RET = re-arranged during transfection SAE = serious adverse event VEGFR = vascular endothelial growth factor receptor. 27819766 2017
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.050 Biomarker phenotype BEFREE Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors. 26786320 2016
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.050 Biomarker phenotype BEFREE Of the nearly 400 chromosomal rearrangements resulting in oncogenic fusion proteins that have been identified to date, the rearrangements that give rise to RET fusion oncogenes in PTC remain the paradigm for chimeric oncoprotein involvement in solid tumors. 19487296 2009